Farver v. Glaxo Wellcome, Inc.

181 F. Supp. 2d 781, 2001 U.S. Dist. LEXIS 23261, 2001 WL 1739155
CourtDistrict Court, N.D. Ohio
DecidedDecember 14, 2001
Docket3:01CV7103
StatusPublished

This text of 181 F. Supp. 2d 781 (Farver v. Glaxo Wellcome, Inc.) is published on Counsel Stack Legal Research, covering District Court, N.D. Ohio primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Farver v. Glaxo Wellcome, Inc., 181 F. Supp. 2d 781, 2001 U.S. Dist. LEXIS 23261, 2001 WL 1739155 (N.D. Ohio 2001).

Opinion

ORDER

CARR, District Judge.

This is a products liability case based on diversity of citizenship, which existed between the plaintiff and defendant when suit was filed. Plaintiff seeks to recover for injuries allegedly caused by defendant Glaxo Wellcome’s defective prescription medication.

Leave was granted at the case management conference to the plaintiff to join additional parties within a specified deadline. Plaintiffs ensuing motion for leave to file an amended complaint joining additional parties, which she filed within that deadline, was granted without opposition.

The newly joined defendants (the doctor who prescribed the medication, and the pharmacy that filled the prescription) are residents of Ohio, as is the plaintiff. Her claims against them were based on allegations of negligence, and alleged that they committed malpractice when they respectively prescribed and provided defendant Glaxo’s medication to the plaintiff.

As a result of the filing of the amended complaint and its joinder of the additional defendants, diversity of citizenship no longer exists between the plaintiff and all defendants.

Pending is plaintiffs motion to dismiss without prejudice on the basis that her joinder of non-diverse defendants deprives this court of jurisdiction. (Doc. 22). Defendant opposes the motion. (Doc. 26). For the reasons that follow, plaintiffs motion shall be granted.

In Freeport-McMoRan, Inc. v. K N Energy, 498 U.S. 426, 111 S.Ct. 858, 112 L.Ed.2d 951 (1991) (per curiam) the Supreme Court held that substitution of a party under Fed.R.Civ.P. 25 did not destroy preexisting diversity between the original parties. In the context of ruling on the effect of substitution under Rule 25, the Court noted that it had “consistently held that if jurisdiction exists at the time an action is commenced, such jurisdiction may not be divested by subsequent events.” 498 U.S. at 428, 111 S.Ct. 858. In light of that statement, the Court held:

The opinions of the District Court and the Court of Appeals establish that the plaintiffs and defendant were diverse at the time the breach-of-contract action arose and at the time that federal pro- *783 eeedings commenced. The opinions also confirm that FMPO was not an “indispensable” party at the time the complaint was filed; in fact, it had no interest whatsoever in the outcome of the litigation until sometime after suit was commenced. Our cases require no more than this. Diversity jurisdiction, once established, is not defeated by the addition of a nondiverse party to the action. A contrary rule could well have the effect of deterring normal business transactions during the pendency of what might be lengthy litigation. Such a rule is not in any way required to accomplish the purposes of diversity jurisdiction.

Id.

After Freeportr-McMoRan, litigants seized on the Court’s broad statement about jurisdiction not being divested by subsequent events, where it existed when the complaint was filed. In response, most courts concluded that the language and holding of Freeport-McMoRan were limited to substitutions under Rule 25, and were not applicable to joinder under Rule 19. Estate of Alvarez v. Donaldson Co., Inc., 213 F.3d 993, 994 (7th Cir.2000) (Freeport-McMoRan “looked at a limited part of diversity in which there was a substitution of parties.”); Cobb v. Delta Exports, Inc., 186 F.3d 675, 680 (5th Cir.1999) (“diversity jurisdiction is unaffected by post-removal joinder of dispensable, non-diverse parties pursuant to Fed. R.Civ.P. 19.”); Ingram v. CSX Transp., Inc., 146 F.3d 858, 861 (11th Cir.1998) (“the holding in Freeport-McMoRan relies upon the assignee’s having been substituted as a plaintiff under Fed.R.Civ.P. 25(c)”); Bishop v. Moore, 2000 WL 246583, at *2-3 (D.Kan. Feb.4, 2000) (“The Free-port-McMoRan holding is limited to the issue of substitution of parties pursuant to Fed.R.Civ.P. 25”). Accord Doleac ex rel. Doleac v. Michalson, 264 F.3d 470, 476 (5th Cir.2001); Omni Equities, Inc. v. Pearl S. Buck Foundation, 850 F.Supp. 290 (E.D.Pa.1994) (“substitution of parties [presents] a vastly different set of circumstances than those under scrutiny here, where Rule 19(b) was invoked”).

Some courts, like the parties’ briefs in this case, have noted the reference in Freeport-McMoRan to that status of the newly joined defendant in that case as “indispensable,” 498 U.S. at 428, 111 S.Ct. 858, and thus have focused on whether the newly joined parties are indispensable or nondispensible under Rule 19(a). See Whalen v. Carter, 954 F.2d 1087, 1095-96 (5th Cir.1992); Kerr v. Smith Petroleum Co., 889 F.Supp. 892, 895 (E.D.La.1995). That focus is misplaced, because, as the foregoing cases make clear, Freeport-McMoRan is limited to substitutions under Rule 25, and has no application to joinders under Rule 19.

Focus on the issue of indispensability/nondispensibility under Rule 19 is also misdirected because it disregards the express terms of 28 U.S.C. § 1447(e), which provide: “If after removal the plaintiff seeks to join additional defendants whose joinder would destroy subject matter jurisdiction, the court may deny joinder, or permit joinder and remand the action to the State court.”

Under § 1447(e), as noted in Casas Office Machines, Inc. v. Mita Copystar America, Inc., 42 F.3d 668, (1st Cir.1994), “joinder or substitution of nondiverse defendants after removal destroys diversity jurisdiction, regardless whether such defendants are dispensable or indispensable to the action.” (citing Yniques v. Cabral, 985 F.2d 1031, 1034 (9th Cir.1993); Washington Suburban Sanitary Comm’n v. CRS/Sirrine, Inc., 917 F.2d 834, 835 (4th Cir.1990); Rodriguez by Rodriguez v. Abbott Lab., 151 F.R.D. 529, 533 n. 6 (S.D.N.Y.1993); Righetti v. Shell Oil Co., *784 711 F.Supp. 531, 535 (N.D.Cal.1989); Vasilakos v.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
181 F. Supp. 2d 781, 2001 U.S. Dist. LEXIS 23261, 2001 WL 1739155, Counsel Stack Legal Research, https://law.counselstack.com/opinion/farver-v-glaxo-wellcome-inc-ohnd-2001.